Novartis Targets Chronic Urticaria As Ligelizumab Enters Late-Stage Trials
Two Phase III studies, PEARL 1 and PEARL 2, will compare Novartis's candidate anti-IgE antibody with the previous generation anti-IgE MAb, Xolair, for the treatment of chronic spontaneous urticaria.
You may also be interested in...
Novartis’s Ligelizumab Founders In Phase III Despite Positive Predictions
Novartis’s ligelizumab failed to show superiority over standard of care Xolair, subverting hopeful analyst expectations and changing the firm’s focus in chronic spontaneous urticaria to a BTK inhibitor asset.
Keeping Track: US FDA Approves Esperoct, Tightens Chantix Label, Starts Review Of Alder’s CGRP Candidate
The latest drug development news and highlights from our US FDA Performance Tracker.
ICER On Asthma Biologics: 50%-79% Price Discounts Needed To Meet Value Assessment Metrics
The independent value assessment organization’s draft assessment found that the prices for all five marketed biologics for severe asthma – Xolair, Nucala, Cinqair, Fasenra and Dupixent – far exceed standard cost-effectiveness thresholds.